Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews@ESMO2018

medwireNews was in Munich for the ESMO 2018 Congress. Click through for all the research news and expert interviews.

Our Editorial Board

Editor's pick

06-11-2018 | Cancer immunotherapy | Editorial | Article

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research

12-11-2018 | Bladder cancer | Highlight | News

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

Specialty

Latest from across the site

20-11-2018 | Article

First-line peripheral T-cell lymphoma, AML drug use announced

First-line peripheral T-cell lymphoma, AML drug use announced

Read more on these US FDA and UK NICE approvals here

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

19-11-2018 | Checkpoint blockade | News

Clinically important safety differences found among immune checkpoint inhibitors

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

Source:

BMJ 2018; 363: K4266

15-11-2018 | Prostate cancer | Podcast | Audio

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).

Click here for the accompanying news story.

15-11-2018 | Renal cell carcinoma | News

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30648-X
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30674-0

13-11-2018 | Non-small cell lung cancer | News

Lorlatinib shows promising activity against ALK-positive advanced NSCLC

Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30649-1
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30789-7

Steering improved outcomes in non-driver mutation lung cancer: Progress and challenges

Steering improved outcomes in lung cancer

This program was made possible thanks to an independent educational grant from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Scientific summary

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits